Expression and localisation of phosphorylated and total JAK2 and STAT3 in control, paclitaxel and paclitaxel plus CYT387-treated ascites derived tumor cells. (A) Expression and immunolocalisation of phospho (P)-JAK2 (Tyr-1007/1008) and total (T)-JAK2 in control, paclitaxel, CYT387 and combination of both treatments in ascites-derived tumor cells was evaluated as described in Figure 6A. Images are representative of three independent experiments performed in triplicate using three independent patient samples. Significant variations between the groups are indicated by **P<0.01, ***P < 0.001. (B) The expression of phospho (P)-STAT3 and total (T)-STAT3 was evaluated and quantified as described in Figure 6A. Significant variations between the groups are indicated by **P<0.01, ***P < 0.001. Magnification 200x; scale bar = 10 μM.
Abubaker et al. BMC Cancer 2014 14:317 doi:10.1186/1471-2407-14-317